Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701891 | 0.82 | RAPGEF4 (0.33) | RAPGEF4CES2CES1ALDH1A1CA12 | |
| SCHEMBL5701821 | 0.71 | CA1 (0.33) | CES2CES1CA12CA1 | |
| SCHEMBL5702104 | 0.71 | ACHE (0.39) | CES2CES1ALDH1A1ERN1 | |
| SCHEMBL67360 | 0.65 | RAPGEF4 (0.42) | RAPGEF4CES2CES1ALDH1A1CA12 | |
| SCHEMBL2929573 | 0.65 | CES2 (0.36) | RAPGEF4CES2CES1ALDH1A1CA12 | |
| SCHEMBL12578957 | 0.63 | CES2 (0.39) | RAPGEF4CES2CES1ALDH1A1CA12 | |
| SCHEMBL531337 | 0.63 | CES2 (0.52) | RAPGEF4CES2CES1ALDH1A1CA12 | |
| Chloromethane SCHEMBL27844640 | 0.63 | CES2 (0.46) | RAPGEF4CES2CES1ALDH1A1CA12 | |
| Phosphine SCHEMBL28854043 | 0.63 | CES2 (0.35) | RAPGEF4CES2CES1ALDH1A1CA12 | |
| SCHEMBL5637066 | 0.61 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1211256-B1 | Method for purifying fluoroaryl metal compound | NIPPON CATALYTIC CHEM IND (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-6509488-B2 | Magnesium halide is precipitated and removed from solution containing fluoroaryl metal compound, magnesium halide, and ether solvent, or magnesium halide is removed by treating solution with acid | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-1211256-A2 | Method for purifying fluoroaryl metal compound | Nippon Shokubai Co., Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-20020065425-A1 | Method for purifying fluoroaryl metal compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065425-A1 | Method for purifying fluoroaryl metal compound | MLLT3, AFF2, AFF4 | RAPGEF4 2395/4885CES2 2108/4885CES1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.